Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new publication related to the study has been added to Publications (Telisotuzumab Vedotin in c-Met+ NSCLC), and the page shows a new revision (v3.6.3) with the older version (v3.6.1) removed, indicating an updated study record.
    Difference
    0.0%
    Check dated 2026-07-02T05:27:02.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision updated from v3.6.0 to v3.6.1, representing a minor publication release of the page. No content changes are indicated by the change data.
    Difference
    0.0%
    Check dated 2026-06-25T04:59:07.000Z thumbnail image
  3. Check
    26 days ago
    Change Detected
    Summary
    Recruitment is now shown as closed for this study, and new navigation links for How to Read a Study Record, Common Questions, and How to Join a Study have been added. There are also minor formatting tweaks to the Intervention/Treatment heading and to the revision notes.
    Difference
    0.1%
    Check dated 2026-06-10T22:08:35.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    Revision version updated from v3.5.4 to v3.5.5, reflecting a minor update to the page's revision tracking.
    Difference
    0.0%
    Check dated 2026-06-03T17:30:23.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Expanded access status on the study page changed from Available (v3.5.3) to Temporarily not available (v3.5.4). This reflects that expanded access is not currently available outside the trial.
    Difference
    0.0%
    Check dated 2026-05-20T07:31:36.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The Taiwan location entry was updated from Taoyuan to Taoyuan City (Taiwan, 333). The postal code remains 333.
    Difference
    0.0%
    Check dated 2026-05-05T22:11:14.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.